S econd-generation metallic drug-eluting stents (DES) have been widely recommended for percutaneous coronary intervention.
Long-Term Outcomes With BVS vs EES
with an increased risk of scaffold thrombosis as compared with EES at 1 year. [7] [8] [9] Furthermore, meta-analyses beyond 1 year also suggested that BVS is associated with worse clinical outcomes 10, 11 ; however, these meta-analyses were limited by inclusion of observational and noncomparative/single arm studies. More recently, the results of a large multicenter trial in all-comers 12 and the 2-year results of the ABSORB III trial (ie, the largest trial to date) have been presented. 13 Therefore, we aimed to conduct a meta-analysis of randomized trials comparing clinical outcomes beyond 1 year with BVS compared with EES for patients with coronary artery disease undergoing percutaneous coronary intervention.
Methods

Data Sources
An electronic search of the Medline database without language restriction was performed from inception through April 2017 using the keywords and Medical Subject Heading: bioresorbable scaffold, drug-eluting stent, and coronary artery disease. Additionally, the Web of Science, the Cochrane Register of Controlled Trials, and major scientific sessions were searched using the same keywords. This metaanalysis was registered at the International Prospective Register of Systematic Reviews or PROSPERO (CRD42015029516) 14 and was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. 15 
Selection Criteria and Data Extraction
Trials that randomized patients with obstructive coronary artery disease undergoing percutaneous coronary intervention to either BVS versus EES were included. We required that trials reported clinical outcomes beyond 1 year. Data from the longest available reported follow-up time was preferentially used. Two independent authors (A.F. Barakat and I.Y. Elgendy) extracted data on study design, sample size, intervention strategies, outcomes, and other study characteristics from the included studies. Discrepancies were resolved by consensus among the authors. The number of clinical events that occurred in each arm of the trial were tabulated.
Outcomes and Definitions
The primary efficacy outcome of interest was target lesion failure (TLF; defined as cardiac death, target vessel myocardial infarction [MI] , and ischemia-driven target lesion revascularization [TLR]), while the primary safety outcome was definite or probable stent/scaffold thrombosis and very late stent/scaffold thrombosis (ie, beyond 1 year) according to the Academic Research Consortium. 16 The secondary outcomes included target vessel MI, ischemia-driven TLR, cardiac mortality, and all-cause mortality.
Quality Assessment
The quality of evidence was evaluated at both the individual study level and at the outcome level. The Cochrane Collaboration's tool for assessing the risk of bias was used to assess the individual study risk of bias. This tool consists of 7 points (random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other sources of bias) that tests for selection, performance, detection, attrition, reporting, and other biases, respectively. 17 Trials with >2 high-risk components were considered as having a moderate risk of bias, and trials with >4 high-risk components were considered as having a high risk of bias.
The overall quality of evidence for each outcome was evaluated using the Grades of Recommendation, Assessment, Development and Evaluation tool. The Grades of Recommendation, Assessment, Development and Evaluation tool grades 4 levels of quality (high, moderate, low, and very low) depending on the type of studies included in the assessment of each outcome; the quality of evidence could be downgraded depending on 5 factors: (1) limitations in the design and implementation of available studies (ie, high likelihood of bias), (2) indirectness of evidence (indirect population, intervention, control, and outcomes), (3) unexplained heterogeneity or inconsistency of results, (4) imprecision of results (ie, wide confidence intervals), and (5) high probability of publication bias.
Statistical Analysis
Outcomes were evaluated by an intention-to-treat analysis. Random effects summary risk ratios (RR) were primarily constructed with DerSimonian-Laird model. 18 Summary odds ratios were also calculated with a Peto model as a secondary analysis. 19 Statistical heterogeneity was assessed using the I 2 statistic. 20 Egger's method was used to calculate publication bias. 21 All P values were 2-tailed, with statistical significance set at 0.05, and confidence intervals (CI) were calculated at the 95% level for the overall estimates effect. All analyses were performed using STATA software version 14 (STATA Corporation, College Station, TX). To determine the impact of certain predictors on definite or probable scaffold thrombosis and very late scaffold thrombosis, random effects meta-regression analyses were prespecified in relation to poststent dilation, acute coronary syndrome, and diabetes mellitus. 22 A sensitivity analysis for the primary efficacy and safety outcomes was performed by excluding single-center trials.
Results
Included Studies
The electronic search yielded 396 articles that were screened by reviewing the title or abstract; we identified 6 trials that met our inclusion criteria (Figure in the Data Supplement). 12, 13, [23] [24] [25] [26] Three reports have been published in peer-reviewed journals, 12, 23, 26 while the 3 other reports were only presented at
WHAT IS KNOWN
• Second-generation metallic drug-eluting stents are associated with a risk of repeat revascularization because of the persistence of the metallic stents in the coronary artery wall.
• Bioresorbable vascular scaffolds have emerged as an attractive breakthrough technology. These scaffolds offer the mechanical support similar to drug-eluting stents followed by complete resolution within 3 to 4 years.
• Meta-analyses of randomized trials suggested that bioresorbable vascular scaffolds might be associated with an increased risk of scaffold thrombosis as compared with everolimus-eluting stents at 1 year.
WHAT THE STUDY ADDS
• This meta-analysis of randomized trials demonstrated that bioresorbable vascular scaffolds are associated with an increased risk of target lesion failure because of an increased risk of target vessel myocardial infarction and target lesion revascularization at a mean of 25 months.
• 13, 24, 25 One trial (ie, ABSORB II) reported the outcomes at both 2 years and at 3 years 23, 27 ; thus, we used the 3-year outcome data. 23 One trial (ie, EVERBIO II) randomized patients to 3 groups: BVS versus EES versus biolimuseluting stents 24 ; therefore, we excluded the biolimus-eluting stents arm because this was not the interest of this metaanalysis. A final number of 6 trials with 5392 patients, 3166 patients in the BVS arm and 2226 patients in the EES arm, were included in this meta-analysis. 12, 13, [23] [24] [25] [26] All the included studies were deemed to be of low risk of bias (Table I in the Data Supplement). All the trials were multicenter, except for the EVERBIO II trial, which was a single-center trial. 24 All the trials reported outcomes at 2 years, except for the ABSORB II trial, which reported outcomes at 3 years, while the ABSORB III trial reported outcomes at 25 months. The weighted mean follow-up duration was 25 months (SD, 3.6 months). A cobalt-chromium EES (Xience) was used as the comparator in all trials, 12, 13, 23, 25, 26 except EVERBIO II where a platinumchromium EES (PROMUS Element) was used. 24 The duration of dual antiplatelet therapy was at least 12 months for the majority of patients in the included trials, except EVER-BIO II 24 (6 months), with reported adherence rates ranging from 80% to 97%. Four trials reported the adherence to dual antiplatelet therapy beyond 1 year (ie, 17.5% and 15.6% in (Figure 2) . The sensitivity analysis excluding the single-center study (ie, EVERBIO II) yielded a similar effect for TLF (RR, 1.33; 95% CI, 1.11-1.60; I 2 =0%; P=0.002). Figure 3) . The sensitivity analysis excluding the single-center study (ie, EVERBIO II) showed similar results for For all of the outcomes that were evaluated in this metaanalysis, there was no evidence of publication bias with Egger's test. The level of evidence was high for all of the outcomes by the Grades of Recommendation, Assessment, Development and Evaluation tool, except for very late stent/ scaffold thrombosis, which was moderate (Table II in the Data Supplement). Table 2 summarizes the summary estimates for the outcomes of interest using DerSimonian-Laird and Peto methods.
Safety Outcomes
Discussion
In this comprehensive meta-analysis of 6 high-quality trials of 5392 patients with coronary artery undergoing percutaneous coronary intervention for noncomplex lesions (mean followup, 25 months), we demonstrated that BVS was associated with an increased risk of TLF, driven by an increased risk of target vessel MI and ischemia-driven TLR. There was a higher risk of definite or probable stent/scaffold thrombosis, as well as very late stent/scaffold thrombosis (ie, beyond 1 year) compared with EES (ie, the best in the class of second-generation DES). The risk of definite or probable scaffold thrombosis and very late scaffold thrombosis did not seem to be influenced by poststent dilation, acute coronary syndrome, and diabetes mellitus. However, the risk of cardiac mortality and all-cause mortality was similar in both groups.
Prior meta-analyses of randomized trials have shown a similar risk of adverse events with both devices at 1 year; however; there was a trend of higher risk of definite or probable scaffold thrombosis with BVS. [7] [8] [9] This meta-analysis, as well as others, 10, 11 demonstrated that the risk of definite or probable scaffold thrombosis was higher with BVS at longer followup. Although data from meta-analysis and real-world studies suggested that the risk of scaffold thrombosis with BVS was driven by a higher incidence of early scaffold thrombosis (<30 days), 7, 28, 29 we have noted that the risk of very late scaffold thrombosis (>1 year) was higher with BVS. In another meta-analysis of 44 studies, the pooled incidence of definite or probable scaffold thrombosis after BVS implantation was 1.5 events per 100 patient-years. 30 While some authors had attributed the potential increased risk of scaffold thrombosis with BVS to the thicker struts (157 μm versus 81 μm with EES), a propensity-matched analysis of 499 patients demonstrated that the risk of periprocedural MI was higher with BVS compared with first-generation sirolimus-eluting stents, which has a similar strut thickness (≈153 μm). 31 These findings indicate that the struts thickness might not be the only contributing factor to the higher risk of scaffold thrombosis. Early discontinuation of dual antiplatelet therapy could be another contributing factor. The compliance to dual antiplatelet therapy ≤1 year was notably high among the included trials in this meta-analysis (>80%). Because of the limited number of studies reporting adherence to dual antiplatelet therapy beyond 1 year, we could not comment on the impact of adherence on dual antiplatelet therapy after 1 year on the outcomes. However, some authors suggested the continuation of dual antiplatelet therapy after BVS implantation for at least 3 years in those without unacceptable side effects. 32 Another important consideration is the optimal scaffold implantation technique. Although postdilation was more predominant with BVS in this study, yet, the risk of stent/scaffold thrombosis was higher with BVS. Our meta-regression analysis did not show that the risk of scaffold thrombosis was influenced by postdilation. The lack of the impact of postdilation on scaffold thrombosis in our study could be explained by the low number of studies included in the meta-regression analysis. An interim analysis of the ongoing ABSORB IV study suggested that with optimal high-pressure postdilation (which has been achieved in ≈86% of the patients who have been enrolled this far), the risk of stent/scaffold thrombosis was lower than what was observed in this meta-analysis (0.4% at 30 days and 0.5% at 1 year for the pooled data for both EES and BVS). 13 Therefore, based on the available data, it is important to adhere to adequate lesion preparation, treating appropriately sized vessels, and postdilation during implantation of BVS. In DES studies, intravascular ultrasound guidance has been shown to improve clinical outcomes at a mean of 15 months. 33, 34 Similarly, in a real-world cohort of 400 lesions (74.8% were type B2/C) treated with BVS in 264 patients, an optimal implantation strategy with more liberal use of intravascular imaging (≈86%) was adopted. Definite or probable scaffold thrombosis occurred in 3 patients at 2 years. 35 A systematic review of intracoronary imaging findings of late and very late BVS thrombosis showed that malposition (9/26), late discontinuity (8/26), peri-strut low-intensity area (5/26), uncovered struts (4/26), underdeployment (4/26), incomplete lesion coverage (3/26), recoil (3/26), and restenosis (2/26) were the potential mechanisms of late and very late BVS thrombosis. 36 Some of these underlying mechanisms (ie, late discontinuity, recoil, peri-strut low intensity area, and restenosis) might not be modified with an optimum implantation strategy. 37 In our study, there were only 2 cases of very late stent thrombosis noted with EES (both cases were in the AIDA trial), compared with 25 cases of very late scaffold thrombosis across the 6 trials. The US Food and Drug administration had recently issued a letter to physicians about the increased risk of major adverse cardiac events with Absorb™ BVS and to follow the instructions for target vessel selection (eg, avoiding BVS use in small heart vessels) 38 ; the results of our meta-analysis further add to the concerns of increased risk of adverse events with BVS.
To the best of our knowledge, this is the largest meta-analysis of randomized trials to date that evaluated the long-term efficacy and safety of BVS compared with EES. Despite the robust methodology, this meta-analysis is not without limitations. First, is important to note that these patients enrolled in most of the included randomized trials had rather simple lesions and excluded the lesions with higher risk of failure; therefore, the generalizability of these results to real-world practice might be limited. However, one of the included studies (ie, AIDA) examined the use of BVS in routine practice and yet demonstrated an increased risk of scaffold thrombosis with BVS. 12 Second, lack of patient-level data precluded a careful evaluation for the patient and lesion characteristics (ie, vessel size) that would benefit from BVS. Thus, we performed multiple study-level meta-regression analyses and demonstrated that none of these baseline characteristics had an influence on the outcomes of scaffold thrombosis and very late scaffold thrombosis. Third, we could not assess the impact of dual antiplatelet therapy adherence beyond 1 year on the outcomes because of the limited number of studies that commented on dual antiplatelet therapy adherence beyond 1 year. Finally, there was a few number of events for both cardiac mortality and very late stent/scaffold thrombosis (with a wide CI), and thus, a firm conclusion could not be drawn for these outcomes.
Conclusions
Data from randomized trials (at a mean follow-up of 25 months) indicate that BVS, compared with EES, had an increased risk of TLF that is primarily driven by the higher incidence of target vessel MI and ischemia-driven TLR. The risk of definite or probable stent/scaffold thrombosis and very late stent/scaffold thrombosis was higher with BVS. Further information from randomized trials is critical to fully evaluate clinical outcomes with BVS on complete resolution of the scaffold.
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